Synmosa Biopharma (4114) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Synmosa Biopharma stock TWD 21.91, price TWD 27.20, that is 19.4% below the price, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 12.28 TWD – 142.73 TWD · fair‑value band 11.03 TWD – 37.35 TWD · the 27.20 TWD price screens above the 21.91 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Synmosa Biopharma in your weekly email
Every Wednesday you see whether Synmosa Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally.
Show moreShow less
It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays.
The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale retail of environmental drugs; and import and export of related businesses. The company was founded in 1959 and is based in Taipei, Taiwan.
Stock analysis
Synmosa Biopharma (4114) currently trades at 27.20 TWD, while our model-based Fair Value estimate is 21.91 TWD, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 33.87 TWD per share, and 8 of the 26 models we run sit above the 27.20 TWD price.
Bear case: the Asset-Based group reads lowest at 2.84 TWD, and 18 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 11.03 TWD (bear) to 37.35 TWD (bull), the price of 27.20 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Synmosa Biopharma reported revenue of 6.2B TWD in FY2025 versus 3.2B TWD in FY2021, a compound +17.6%/yr. Reported net income was 822M TWD in FY2025, compounding +28.2%/yr from FY2021.
Key figures
Market cap 13.8B TWD (≈ $420M) Small · P/E ratio 17.4 · P/S ratio 2.06 · EPS (TTM) 1.56 TWD · Dividend yield 2.9% · Net margin 12.4% · Return on equity 5.9% · Return on assets (EBIT) 4.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −19%, 4114 screens cheaper than that median.
Fair Value models
Bear11.03 TWDFair Value 21.91 TWDBull37.35 TWD
Price 27.20 TWD · Downside -19.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.6608 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.7%
Dividend (yield on the price)2.9%
Per share before 2026divided by the spin-off factor 1.0798
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+50.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +47.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−19.4% · Below median
Profitability
Return on equity (12 months)5.9% · Below median
Return on assets5.9% · Above median
Net margin (12 months)12.4% · Above median
Operating margin (12 months)11.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)19.2% · Top 25%
Dividend yield (12 months)2.9% · Above median
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Synmosa Biopharma Fair Value". https://www.fairvalue-calculator.com/stock/4114
Frequently asked questions
Is Synmosa Biopharma (4114) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 21.91 TWD versus a price of 27.20 TWD, about 19% lower (overvalued).
What is the fair value of 4114?
Our model-based fair value for Synmosa Biopharma is 21.91 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 27.20 TWD.
What is the quality score of 4114?
Synmosa Biopharma has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Synmosa Biopharma (4114)?
Our model-based price target is the fair value of 21.91 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 11.03 TWD, optimistic scenario 37.35 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Synmosa Biopharma stock forecast for 2026?
Our models put fair value at 21.91 TWD, about 19% lower versus a price of 27.20 TWD (overvalued). Cautious scenario 11.03 TWD, optimistic scenario 37.35 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Synmosa Biopharma (4114)?
Synmosa Biopharma reported trailing-twelve-month revenue of about 6.7B TWD (latest available figure, as of Nov 8, 2026).
Does Synmosa Biopharma pay a dividend?
Synmosa Biopharma currently shows a dividend yield of 2.89% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Synmosa Biopharma (4114) and when is the ex-dividend date?
Synmosa Biopharma pays a dividend of 0.787 TWD per share a year, a dividend yield of 2.9%. The last ex-dividend date was Jul 17, 2026. A dividend has been paid every year since 2011. The payout ratio is 50.4% of earnings. Free cash flow covers the dividend 0.32 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Synmosa Biopharma (4114)?
For today's price to be fair in a discounted-cash-flow model, Synmosa Biopharma would have to grow free cash flow by +50.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.3 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4114 use?
Our models discount Synmosa Biopharma at 11.8 %: a base by market capitalisation (small), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Synmosa Biopharma that is +50.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Synmosa Biopharma (4114) delivered so far?
Over the past 5 years revenue at Synmosa Biopharma grew +15.3 % a year. The price currently implies free-cash-flow growth of +50.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Synmosa Biopharma (4114) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Synmosa Biopharma (+50.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Synmosa Biopharma (4114)?
The free-cash-flow yield on the price is 0.95 %: that much free cash flow Synmosa Biopharma produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Synmosa Biopharma (4114)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Synmosa Biopharma it is 21.91 TWD per share (as of Nov 8, 2026), against a price of 27.20 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Synmosa Biopharma stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4114 trades above its calculated fair value: price 27.20 TWD, fair value 21.91 TWD, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4114?
No. The price is what the market pays today (27.20 TWD); the fair value is what the company's own numbers justify (21.91 TWD). For Synmosa Biopharma the two are 5.29 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Synmosa Biopharma worth?
The market values Synmosa Biopharma at about 13.8B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 27.20 TWD; our models calculate a fair value of 21.91 TWD per share.
What do the bullish and bearish scenarios say about 4114?
Our models span a range for Synmosa Biopharma: cautious scenario 11.03 TWD, base 21.91 TWD, optimistic 37.35 TWD per share (as of Nov 8, 2026, price 27.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4114?
Synmosa Biopharma trades at a price-to-earnings ratio of 17.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.91 TWD is built from several models across several years. Other multiples: P/B 1.6, P/S 2.1, EV/EBITDA 13.0.
How solid is the balance sheet of Synmosa Biopharma (4114)?
Balance-sheet figures for Synmosa Biopharma (as of Nov 8, 2026): return on equity 5.9%, debt of 0.18 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 4114 from its 52-week high?
Synmosa Biopharma trades at 27.20 TWD, about 13% below its 52-week high of 31.25 TWD and 1% above the low of 27.06 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 21.91 TWD is for.
Which stocks are comparable to Synmosa Biopharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Synmosa Biopharma stock attractive at the current price?
The data as of Nov 8, 2026: price 27.20 TWD, calculated fair value 21.91 TWD (−19%), Quality Score 40/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4114 calculated?
We run Synmosa Biopharma through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 21.91 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Synmosa Biopharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Synmosa Biopharma (4114)?
The closing price on Nov 6, 2026 was 27.20 TWD. Our model-based fair value is 21.91 TWD, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Synmosa Biopharma right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (11.03 TWD to 37.35 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Synmosa Biopharma
How large is the market capitalisation of Synmosa Biopharma (4114)?
The market capitalisation of Synmosa Biopharma is 13.8B TWD (≈ $420M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Synmosa Biopharma (4114)?
The price-to-sales ratio of Synmosa Biopharma is 2.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Synmosa Biopharma (4114)?
Earnings per share at Synmosa Biopharma are 1.56 TWD (price ÷ EPS = P/E 17.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Synmosa Biopharma (4114)?
The dividend yield of Synmosa Biopharma is 2.9% (payout 50.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Synmosa Biopharma (4114)?
The net margin of Synmosa Biopharma is 12.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Synmosa Biopharma (4114)?
The return on equity (ROE) of Synmosa Biopharma is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Synmosa Biopharma (4114)?
On an EBIT basis the return on assets of Synmosa Biopharma is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Synmosa Biopharma (4114)?
The operating margin of Synmosa Biopharma is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Synmosa Biopharma (4114)?
Revenue at Synmosa Biopharma is growing +19.2% versus a year earlier (3y avg +12.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Synmosa Biopharma (4114)?
Earnings per share at Synmosa Biopharma are growing +10.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Synmosa Biopharma (4114) carry?
The net debt of Synmosa Biopharma is 566M TWD (fiscal year 2025, ≈ 4.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Synmosa Biopharma in the live analysis
One click puts Synmosa Biopharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026